Free Alerts   Login
Health Care › Services-Commercial Physical And Biological Research

CRL Stock Price Correlated With Charles River Laboratories International Financials

CRL Stock Price vs. Quarterly
CRL
Income Statement
Cash Flow
Balance Sheet

CRL Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

CRL Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

CRL Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Vanguard Group
5,980,306 sh
26,446 sh
0%
$1,413,745
$246,907
Blackrock.
5,161,360 sh
40,793 sh
1%
$1,220,147
$216,618
State Street
2,059,785 sh
33,985 sh
2%
$486,933
$89,917
Kayne Anderson Rudnick Investment Management
1,753,238 sh
7,137 sh
0%
$414,466
$72,265
Clearbridge Investments
1,468,059 sh
-277,935 sh
-16%
$347,049
$4,869
Price T Rowe Associates /Md/
1,443,175 sh
-237,498 sh
-14%
$341
$11
Allspring Global Investments Holdings
1,165,306 sh
-29,920 sh
-3%
$275,478
$41,238
Meritage Group Lp
1,155,376 sh
271,743 sh
31%
$273,131
$99,957
Geode Capital Management
1,146,009 sh
23,186 sh
2%
$270,219
$50,641
Ariel Investments
1,050,698 sh
-15,902 sh
-1%
$248,386
$39,354
Southpoint Capital Advisors
1,000,000 sh
200,000 sh
25%
$236,400
$79,616
Invesco.
948,318 sh
20,423 sh
2%
$224,182
$42,334
Mackenzie Financial
917,858 sh
-5,791 sh
-1%
$216,982
$39,937
Earnest Partners
889,368 sh
83,485 sh
10%
$210,247
$52,310
Franklin Resources
763,015 sh
-18,486 sh
-2%
$180,377
$27,217
Bank Of America /De/
736,108 sh
726,108 sh
7261%
$174,016
$172,056
Montrusco Bolton Investments.
722,091 sh
-133,296 sh
-16%
$167,388
$3,330
FIL
662,650 sh
125,000 sh
23%
$156,650
$51,281
Sei Investments
568,207 sh
110,494 sh
24%
$134,324
$44,622
Wells Fargompany/Mn
545,525 sh
-27,223 sh
-5%
$128,963
$16,716
COMPANY PROFILE
BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2021. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations.

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

Newly Issued Accounting Pronouncements

In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities About Government Assistance.” ASU 2021-10 requires disclosures about transactions with a government that have been accounted for by a grant or contribution accounting model to increase transparency about the types of transactions, the accounting for the transactions, and the effect on the financial statements. The ASU is an annual disclosure effective for fiscal years beginning after December 15, 2021 and will be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements and related disclosures, but does not believe there will be a material impact.

Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for fiscal year 2021.

Consolidation

The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.

The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end, which will occur in this fiscal year 2022.

Segment Reporting

The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing S

Free historical financial statements for Charles River Laboratories International Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 52 quarters since 2011. Compare with CRL stock chart to see long term trends.

Data imported from Charles River Laboratories International Inc. SEC filings. Check original filings before making any investment decision.